4660 La Jolla Village Drive
Suite 100
San Diego, CA 92122
United States
650 800 3717
https://www.revbiosciences.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 9
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. James M. Rolke | CEO & Director | 649,25k | N/D | 1969 |
Mr. Chester Stanley Zygmont III | CFO & Corporate Secretary | 479,14k | N/D | 1980 |
Ms. Sandra Vedrick | Vice President of Human Resources & Investor Relations | N/D | N/D | N/D |
Ms. Carol Odle | Senior Director of Clinical Projects | N/D | N/D | N/D |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
L'ISS Governance QualityScore di Revelation Biosciences, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.